Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RENESE-R vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Thiazide diuretic; inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and water reabsorption.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Edema due to congestive heart failure,Mild to moderate hypertension
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
Initial: 5 mg orally once daily, increased as needed to 10 mg once daily; maximum 10 mg/day.
250 mg orally twice daily
Terminal elimination half-life: 13-16 hours; clinical context: supports once-daily dosing
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Metabolized by liver (CYP450) to active metabolite; excreted in feces (65%) and urine (35%).
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Renal: 50% unchanged; fecal: 0%; biliary: 0%
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
80-90% bound to plasma proteins, primarily albumin
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
0.2-0.3 L/kg; indicates distribution mainly in extracellular fluid
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral: 70-80%
70-90% (oral); 100% (IV).
GFR 30-50 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Not approved for use in pediatric patients; safety and efficacy not established.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Initiate at 2.5 mg orally once daily; use caution due to increased sensitivity to electrolyte disturbances and hypotension.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
No FDA boxed warning.
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
May cause hypokalemia and hypomagnesemia,Can precipitate hyperuricemia and gout,May increase serum calcium,Use with caution in diabetes (may increase blood glucose),Photosensitivity reactions reported,Sulfonamide allergy: possible cross-reactivity
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Anuria,Hypersensitivity to sulfonamides or thiazides,Severe renal impairment (creatinine clearance <30 m L/min),Hepatic coma or pre-coma
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid excessive salt intake as it can reduce the antihypertensive effect. Limit alcohol consumption, which may enhance orthostatic hypotension. High-potassium foods (e.g., bananas, oranges, spinach) are generally safe but monitor potassium levels as thiazides can cause hypokalemia; supplement potassium if indicated. Grapefruit juice has no known interaction with this combination.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
Renese-R (polythiazide) is a thiazide diuretic. Use in pregnancy, especially during the first and second trimesters, is associated with an increased risk of fetal or neonatal jaundice, thrombocytopenia, and possible other adverse reactions that have occurred in adults. Because thiazides cross the placental barrier and appear in cord blood, use during the third trimester may cause electrolyte disturbances, hypoglycemia, and other effects. The drug should be used only if clearly needed and if the potential benefit justifies the potential risk to the fetus.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Thiazides are excreted in human milk in small amounts. There is no published M/P ratio for polythiazide specifically; however, based on thiazide class, the M/P ratio is approximately 0.1-0.5. Breastfeeding is generally discouraged due to potential for adverse effects in the infant, including electrolyte imbalance and thrombocytopenia. Alternative agents are preferred, especially in high-dose therapy or when monitoring is not feasible.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
Pregnancy may alter pharmacokinetics of thiazides due to increased plasma volume and renal blood flow. Dose adjustments are not well established; however, polythiazide should be used at the lowest effective dose to avoid excessive diuresis and electrolyte imbalances. If used, monitor maternal electrolytes and renal function closely. The dose may need to be reduced if signs of hypovolemia or electrolyte abnormalities develop. Postpartum, consider dose readjustment as plasma volume normalizes.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
Renese-R is a fixed-dose combination of polythiazide, a thiazide diuretic, and reserpine, a Rauwolfia alkaloid antihypertensive. Watch for hypokalemia, especially in patients on digoxin. Reserpine can cause significant bradycardia and depression; avoid in patients with history of depression. Discontinue at least 2 weeks before electroconvulsive therapy. Monitor for orthostatic hypotension, especially when used with other antihypertensives.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Avoid alcohol and standing up quickly from lying or sitting positions to prevent dizziness.,Report symptoms of depression, severe drowsiness, or slow heartbeat to your doctor immediately.,You may need to have regular blood tests to monitor potassium levels and kidney function.,This medication can cause increased sensitivity to sunlight; use sunscreen and protective clothing.,Do not stop taking this drug abruptly without consulting your doctor.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RENESE-R vs ALDOCLOR-250, answered by our medical review team.
RENESE-R is a Antihypertensive Combination that works by Thiazide diuretic; inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and water reabsorption.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RENESE-R and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RENESE-R is: Initial: 5 mg orally once daily, increased as needed to 10 mg once daily; maximum 10 mg/day.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RENESE-R and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RENESE-R is classified as Category C. Renese-R (polythiazide) is a thiazide diuretic. Use in pregnancy, especially during the first and second trimesters, is associated with an increased risk of fetal or neonatal jaund. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.